CNS opioid signaling separates cannabinoid receptor 1-mediated effects on body weight and mood-related behavior in mice

Sarah Haas Lockie, Traci A. Czyzyk, Nilika Chaudhary, Diego Perez-Tilve, Stephen C. Woods, Brian J. Oldfield, Michael A. Statnick, Matthias H. Tschöp

Research output: Contribution to journalArticlepeer-review

21 Scopus citations

Abstract

Existing monotherapies for the treatment of obesity provide only modest weight loss and/or have adverse side effects, and this is also the case with the cannabinoid receptor 1 (CB1) inverse agonist, rimonabant. We aimed to investigate the possibility of improving efficacy and reducing side effects of rimonabant by cotreatment with opioid system antagonists. Using both genetic and pharmacological removal of opioid signaling in mice, we investigated changes in body weight, food intake, and fat mass as well as behavioral outcomes of interactions between opioid ligands and the CB1 using the inverse agonist, rimonabant. The ability of rimonabant to reduce weight is enhanced by removal of with μ-opioid receptor signaling, while not being greatly affected by κ-opioid receptor blockade. Additionally, lack of opioid signaling, especially κ-opioid receptor, attenuated the ability of rimonabant to decrease immobility time in the Porsolt forced-swim test, a preclinical model of depression. These results indicate that the endogenous opioid system is involved in modulating both the metabolic and mood effects of rimonabant.

Original languageEnglish (US)
Pages (from-to)3661-3667
Number of pages7
JournalEndocrinology
Volume152
Issue number10
DOIs
StatePublished - Oct 2011

All Science Journal Classification (ASJC) codes

  • Endocrinology

Fingerprint Dive into the research topics of 'CNS opioid signaling separates cannabinoid receptor 1-mediated effects on body weight and mood-related behavior in mice'. Together they form a unique fingerprint.

Cite this